VORSCHAU

PRESSETERMINE




WETTER
Graz: Regen
Innsbruck: bedeckt
Linz: Regen
Wien: bedeckt
© wetter.net

Stadtname / PLZ

AKTIENKURSE
 
ADHOC
Mi, 11.05.2016 03:15
Meldung drucken Artikel weiterleiten
pta20160511004
Public disclosure of inside information according to article 17 MAR
Pressefach Pressefach

Biofrontera AG: FDA grants approval for Ameluz® in the USA

Leverkusen (pta004/11.05.2016/03:15) - Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, has received unconditional approval for marketing in the US from the Food and Drug Administration FDA for its prescription drug Ameluz® in combination with the PDT-lamp BF-RhodoLED® for the lesion-directed and field-directed treatment of mild to moderate actinic keratoses on the face and the scalp. FDA has not requested any post-approval obligations.

Further details shall be disclosed in a separate announcement shortly.

Leverkusen, May 11, 2016
The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
e-mail: press@biofrontera.com

(Ende)

Aussender: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Deutschland
Ansprechpartner: Investor & public relations
Tel.: +49 (0) 214 87 63 20
E-Mail:
Website: www.biofrontera.com
ISIN(s): DE0006046113 (share)
Börsen: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin
Biofrontera AG
   
Wie fanden Sie diese Meldung?
Weitersagen
likes dislike Share Share |
Social Media
ETARGET

FOCUSTHEMA


SPECIALS


Werbung
middleAdvertising